Literature DB >> 32714541

Quantitative evaluation of chemotherapy-induced peripheral neuropathy by using intraepidermal electrical stimulation.

Fumie Oyama1, Masayuki Futagami1, Hiroe Oikiri1, Anna Takabayashi1, Asami Akaishi1, Tomoe Kodama1, Mami Matsumoto1, Masahiro Kanamori1, Maika Oishi1, Rie Miura1, Hachidai Hirakawa1, Yoshihito Yokoyama1.   

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a frequently observed treatment-related adverse effect, particularly associated with taxane-based chemotherapy, which affects the quality of life of the patients. To date, CIPN has been subjectively evaluated by patients or physicians. Intraepidermal electrical stimulation (IES) may be applied to evaluate the function of small fibers by measuring pain threshold, and assess the degree of diabetic peripheral neuropathy. The aim of the present study was to evaluate CIPN objectively by using IES. The pain threshold measured by IES in patients with gynecological cancer who underwent taxane-based chemotherapy was compared with the clinical grading scale of peripheral neuropathy (National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0). A total of 57 patients were evaluated (151 measurements). The median age of the patients was 63 years. The number of measurements with clinical grades of 0, 1 and ≥2 was 49, 57 and 45, respectively. The mean pain threshold was 0.1, 0.14 and 0.18 mA for grades 0, 1 and ≥2, respectively. Therefore, the mean pain threshold significantly increased with the progression of the clinical grade. The measurement of pain threshold by using IES may be a reliable indicator for quantitative evaluation of CIPN.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  chemotherapy-induced peripheral neuropathy; intraepidermal electrical stimulation; objective measurement; paclitaxel; quantitative evaluation

Year:  2020        PMID: 32714541      PMCID: PMC7366225          DOI: 10.3892/mco.2020.2056

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  18 in total

1.  Elevated pain threshold in patients with asymptomatic diabetic neuropathy: an intraepidermal electrical stimulation study.

Authors:  Chieko Suzuki; Tomoya Kon; Yukihisa Funamizu; Tatsuya Ueno; Rie Haga; Haruo Nishijima; Akira Arai; Masahiko Tomiyama; Masayuki Baba
Journal:  Muscle Nerve       Date:  2016-06       Impact factor: 3.217

2.  Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study.

Authors:  Jennifer S Gewandter; Jenna Chaudari; Chinazom Ibegbu; Rachel Kitt; Jennifer Serventi; Joy Burke; Eva Culakova; Noah Kolb; Kathleen A Sluka; Mohamedtaki A Tejani; Nimish A Mohile
Journal:  Support Care Cancer       Date:  2018-08-27       Impact factor: 3.603

3.  Pain perception in humans: use of intraepidermal electrical stimulation.

Authors:  Koji Inui; Ryusuke Kakigi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-12-03       Impact factor: 10.154

4.  Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors.

Authors:  L Eckhoff; As Knoop; M B Jensen; M Ewertz
Journal:  Eur J Cancer       Date:  2014-12-22       Impact factor: 9.162

5.  Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations.

Authors:  Kathleen A Griffith; Darren J Couture; Shijun Zhu; Naimish Pandya; Mary E Johantgen; Guido Cavaletti; Joan M Davenport; Lori J Tanguay; Amanda Choflet; Todd Milliron; Erica Glass; Nancy Gambill; Cynthia L Renn; Susan G Dorsey
Journal:  Support Care Cancer       Date:  2013-12-21       Impact factor: 3.603

6.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Authors:  Paul A Vasey; Gordon C Jayson; Alan Gordon; Hani Gabra; Rob Coleman; Ronnie Atkinson; David Parkin; James Paul; Andrea Hay; Stan B Kaye
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

7.  Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.

Authors:  Sandro Pignata; Sabino De Placido; Rosalbino Biamonte; Giovanni Scambia; Giovanni Di Vagno; Giuseppe Colucci; Antonio Febbraro; Marco Marinaccio; Alessandra Vernaglia Lombardi; Luigi Manzione; Giacomo Cartenì; Mario Nardi; Saverio Danese; Maria Rosaria Valerio; Andrea de Matteis; Bruno Massidda; Giampietro Gasparini; Massimo Di Maio; Carmela Pisano; Francesco Perrone
Journal:  BMC Cancer       Date:  2006-01-07       Impact factor: 4.430

8.  Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device.

Authors:  Ayumu Matsuoka; Ayako Mitsuma; Osamu Maeda; Hiroaki Kajiyama; Hitoshi Kiyoi; Yasuhiro Kodera; Masato Nagino; Hidemi Goto; Yuichi Ando
Journal:  Cancer Sci       Date:  2016-09-02       Impact factor: 6.716

9.  Objective evaluation of chemotherapy-induced peripheral neuropathy using quantitative pain measurement system (Pain Vision®), a pilot study.

Authors:  Junya Sato; Megumi Mori; Satoru Nihei; Satoshi Takeuchi; Masahiro Kashiwaba; Kenzo Kudo
Journal:  J Pharm Health Care Sci       Date:  2017-07-25

10.  Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis

Authors:  Ahmed Gaballah; Amr Shafik; Khaled Elhusseiny; Mai Ashraf
Journal:  Asian Pac J Cancer Prev       Date:  2018-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.